Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline

Biohaven Ltd.

Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.
Phase 1 safety data for BHV-7000 (Kv7.2/3 activator) validates differentiated profile; pivotal studies in focal epilepsy and bipolar disorder planned in 2H2023.
Initiated Phase 1 study for BHV-8000 (brain-penetrant TYK2/JAK1 inhibitor); Phase 2 in Parkinson's expected next year.
Global Phase 3 trial of taldefgrobep alfa in SMA enrollment of ~225 patients expected to complete in 2023.
IND for novel IgG degrader BHV-1300 on track for submission in 2023; multiple new INDs planned within next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.